Better adherence to prescribed treatment regimen is related to less chronic pain among adolescents and young adults with moderate or severe haemophilia by McLaughlin, J. M. et al.
ORIGINAL ARTICLE Clinical haemophilia
Better adherence to prescribed treatment regimen is related
to less chronic pain among adolescents and young adults
with moderate or severe haemophilia
J. M. MCLAUGHLIN,* M. L. WITKOP,† A. LAMBING,‡ T. L. ANDERSON,* J. MUNN§ and
B. TORTELLA*
*Medicines Development Group, Pfizer Specialty Care, Collegeville, PA; †Northern Regional Bleeding Disorders Center,
Munson Medical Center, Traverse City; ‡Adult Hemophilia & Thrombosis Treatment Center, Henry Ford Health System,
Detroit; and §Hemophilia Treatment Center, University of Michigan, Ann Arbor, MI, USA
Summary. Little data exist, especially for adolescent
and young adult (AYA) persons with haemophilia
(PWH), about the relationship between adherence to
prescribed treatment regimen and chronic pain. We
examined this relationship among PWH (moderate or
severe) aged 13–25 via cross-sectional survey.
Adherence was assessed using the Validated
Hemophilia Regimen Treatment Adherence Scale
(VERITAS)-Pro and VERITAS-PRN for prophylactic
and on-demand participants respectively. VERITAS
scores range from 24 (most adherent) to 120 (least
adherent). Chronic pain was measured using the FPS-R
and was dichotomized as high for FPS-R scores ≥4 and
low for <4. Logistic regression models were
constructed to assess factors associated with having
high (vs. low) chronic pain. Of 80 AYA respondents
(79 men), most had severe disease (91%), infused
prophylactically (86%) and had haemophilia A (91%).
Fifty-one per cent were aged 13–17 and most were
white (76%), non-Hispanic (88%) and never married
(93%). Chronic pain was reported as high for 35% of
respondents. Mean VERITAS-Pro scores for those with
high and low chronic pain were 53.6  12.3 vs.
47.4  12.9, P = 0.05. VERITAS-PRN scores were
similar across chronic pain status. Logistic regression
revealed that for each 10-point reduction (i.e. increase
in adherence) in the combined VERITAS (Pro and
PRN) and VERITAS-Pro scores there was a 35%
(OR = 0.65; 95%CI = 0.44, 0.96; P = 0.03) and 39%
(OR = 0.61; 95%CI = 0.39, 0.96; P = 0.03) reduction
in odds of having high chronic pain respectively.
Among AYA PWHs, better adherence was associated
with significantly lower odds of having high chronic
pain. Moreover, non-whites were >4 times as likely as
whites to report high chronic pain.
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Introduction
Little data exist, especially for adolescents and young
adults (AYA), about the relationship between level of
adherence to prescribed haemophilia treatment
regimens and chronic pain. Practical experience with
most haemophilia patients has demonstrated that
adherence to both on-demand and prophylactic treat-
ment regimens, although variable, is less than ideal.
According to the National Hemophilia Foundation
(NHF), nearly half of all patients and parents of
patients reported that bleeds were not treated early on
[1]. Other reports have shown that approximately
40% of patients reported not following prescribed
treatment regimens [2] or rated their adherence as less
than excellent [3]. Consequently, many patients expe-
rience serious complications stemming from poor
adherence [3–7]. Specifically, poor adherence to pre-
scribed clotting-factor treatment regimens can lead to
worsened and repeated bleeding episodes in the joints,
muscles and/or soft tissue [5]. Over time these
episodes can lead to complications including haem-
arthropathy, which often manifests itself as debilitat-
ing chronic pain. To help quantify the relationship
between adherence and health outcomes among per-
sons with haemophilia (PWH), several studies have
attempted to measure and/or evaluate the impact of
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adherence [2,3,7–9]. However, because a standardized
and validated measure of adherence was not used in
previous studies, contextualizing and comparing
results have not been possible. Admittedly, previous
authors have recognized this fact [2,3,8,9]. Moreover,
data describing adherence among AYA PWH are par-
ticularly lacking. AYAs are a unique population of
PWH who are often (i) just starting to take more
responsibility for the management of their own disease
and (ii) developing treatment habits that can carry
over into adult life [2]. To that end, the primary aim
of this study was to evaluate the relationship between
a newly validated measure of adherence to prescribed
clotting-factor treatment regimens and chronic pain
among AYAs with moderate or severe haemophilia
using data collected via a large cross-sectional survey
administered in 2012.
Materials and methods
Study population and recruitment
Data describing PWH’s adherence to prescribed treat-
ment regimens and level of chronic pain were
obtained as part of the larger Interrelationship
between Management of Pain, Adherence to Clotting-
factor Treatment and Quality of Life (IMPACT QoL)
study. As the name suggests, the IMPACT QoL study
had the primary goal of assessing the relationship
between validated measures of pain, clotting-factor
adherence and QoL among AYA PWHs and AYAs
with von Willebrand disease (VWD). In addition, as
part of the IMPACT QoL study we also evaluated
how similar an AYA patient’s perceptions of pain,
adherence and QoL were compared to the perceptions
of their carer (e.g. parent or spouse) and their health
care provider. Data were collected via a one-time,
cross-sectional, online survey from a convenience sam-
ple of AYA patients with a bleeding disorder. To be
eligible to complete the survey, participants had to (i)
be aged 13–25 years, (ii) read, write and speak Eng-
lish, and (iii) have haemophilia A, haemophilia B, or
VWD. Recruitment occurred at major US haemophilia
meetings (e.g. Inhibitor Summits and NHF meetings),
US haemophilia treatment centres (HTC), and through
a FacebookTM (Facebook, Menlo Park, CA, USA) page
dedicated to the study from April to December of
2012. All surveys were completed electronically using
SurveyMonkeyTM (SurveyMonkey, Palo Alto, CA,
USA) and Apple iPadsTM (Apple, Cupertino, CA,
USA). The study was approved by the Munson Medi-
cal Center (Traverse City, MI, USA) institutional
review board prior to data collection. All data were
de-identified prior to analysis. This study uses a
patient subset of the IMPACT QoL survey data to
analyse the relationship between adherence to clot-
ting-factor treatment and chronic pain among AYAs
with moderate or severe haemophilia. Patients with
mild haemophilia or VWD were excluded from this
analysis because of small sample size and to mini-
mize heterogeneity in the assessment of the primary
hypothesis.
Measurement
Adherence was assessed using the Validated Hemo-
philia Regimen Treatment Adherence Scale (VERI-
TAS)-Pro [10] and VERITAS-PRN [11] for
prophylactic and on-demand (i.e. episodic) partici-
pants respectively. VERITAS scores range from 24
(most adherent) to 120 (least adherent). As an experi-
mental measure, we also combined VERITAS-Pro and
VERITAS-PRN responses into one category (VERI-
TAS-combined) to evaluate the relationship between
adherence and chronic pain for both prophylactic and
on-demand AYA PWH simultaneously. Chronic pain
was measured using the revised Faces Pain Scale (FPS-
R). The FPS-R is a visual scale composed of six faces
illustrating an increasing level of pain intensity.
Respondents were asked to choose the face that best
describes the intensity of the chronic pain they experi-
enced. In the IMPACT QoL survey, chronic pain was
defined as ‘pain that you have every day or almost
every day, and that always or almost always seems to
be there even when you are not having a bleed at that
moment.’ FPS-R scores range from 0 to 10 with the
faces representing the lowest and highest levels of pain
intensity coded as 0 and 10 respectively. The FPS-R is
highly correlated with the visual analog scale
(r = 0.93) and with the coloured analog scale
(r = 0.84), demonstrating strong validity. Moreover,
reliability and validity of the FPS-R have been estab-
lished for a broad age range, ranging from children as
young as 4 years old to adults [12]. For the purpose
of analysis, chronic pain was dichotomized as high for
those who reported their pain as ‘moderate’, ‘severe’,
‘very severe’, or ‘worst pain possible’ (i.e. ≥4) and low
for ‘mild pain’ or ‘no pain’ (i.e. <4).
Statistical analysis
Descriptive statistics and univariate relationships were
assessed by tabulating chronic pain status by VERI-
TAS scores and patient sociodemographic and clinical
characteristics. Percentages were used to describe cate-
gorical variables and statistical association was
assessed using Fisher’s exact test because of small sam-
ple size. Multivariable, parsimonious logistic regres-
sion models were constructed to assess factors
associated with having high (vs. low) levels of chronic
pain. Separate models were constructed to evaluate (i)
a combined, experimental VERITAS score among
prophylactic and on-demand patients and (ii) the
VERITAS-Pro score among prophylactic patients only.
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Small sample size prevented analysis for on-demand
(only) participants. Due to the large number of vari-
ables collected as part of the survey and because of
the small sample size inherent in rare disease
research, in addition to the fully adjusted models,
final parsimonious models were constructed. In the
final parsimonious models, we decided, a priori, to
model VERITAS score as the primary variable of
interest and include other covariates in the model
only if they (i) changed the odds ratio (OR) of the
VERITAS score parameter by at least 10–15% (i.e.
confounded) [13], (ii) improved the precision of the
estimated VERITAS score parameter, or (iii) were
statistically significant at a two-tailed alpha level of
0.05. All statistical analyses were performed using
SAS 9.2 (SAS, Cary, NC, USA). All P-values were
calculated using two-sided tests.
Results
Ninety-three AYAs with haemophilia completed the
survey. Mild patients (n = 13) were excluded. Of the
80 participants (79 men) included in the final analysis,
most had severe disease (91%), infused prophylacti-
cally (86%) and had haemophilia A (91%). Fifty-one
per cent were aged 13–17 years and most were white
(76%), non-Hispanic (88%) and never married
(93%). Most (73%) of non-white respondents were
black or African American, 14% were mixed race,
9% were Asian and 5% were American Indian or
Alaskan Native. The majority (94%) had some type
of health insurance, with the highest proportion hav-
ing only commercial insurance (45%), only Medicaid
(28%), or both (9%).
Mean VERITAS-Pro (n = 69) and PRN (n = 11)
scores were 49.6  12.9 (range 25–78) and
51.0  11.6 (range 35–74) respectively. Chronic pain
was reported as high for 35% of respondents. The
proportion of respondents who reported having high
levels of chronic pain was similar across treatment
regimen (36% for prophylactic vs. 27% for on
demand, P = 0.74). At the univariate level, patients
with self-reported high levels of chronic pain were
more likely than those who reported low levels of pain
to be young adults (vs. adolescents, P = 0.04), be non-
white (P = 0.01) and have government-provided
health insurance or be uninsured (vs. commercial
health insurance, P = 0.03) (Table 1). Compared to
those with low self-reported chronic pain, those with
high chronic pain had higher (worse adherence) VERI-
TAS-Combined scores (53.1  12.0 vs. 48.0  12.8,
P = 0.08), though not statistically significant at
P < 0.05. Among prophylactic respondents only, mean
VERITAS-Pro scores for those with high chronic pain
were higher (worse adherence) compared to those
who reported low chronic pain (53.6  12.3 vs.
47.4  12.9, P = 0.05). VERITAS-PRN scores were
similar across chronic pain status, though sample size
was small (n = 11). Figure 1 compares VERITAS
scores by chronic pain level.
Adjusted logistic regression analysis revealed that
for each 10-point reduction (i.e. increase in adherence)
in the combined, experimental VERITAS score (Pro
and PRN) there was a 35% (OR = 0.65; 95%
CI = 0.44, 0.96; P = 0.03) reduction in the odds of
having high chronic pain. Among prophylactic respon-
dents only, for each 10-point reduction in the VERI-
TAS-Pro score there was a 39% (OR = 0.61; 95%
CI = 0.39, 0.96; P = 0.03) reduction in the odds of
having high chronic pain (Tables 2 and 3). Among all
and prophylactic-only respondents, respectively, the
model also revealed that, compared to whites, non-
whites were 5.31 (95% CI = 1.62, 17.4; P = 0.01)
and 4.42 (95% CI = 1.21, 16.1; P = 0.02) times as
likely to report high chronic pain (Table 3). History
of inhibitor development was (i) an important
confounder and (ii) increased the precision of the
model. Thus, it remained in all final parsimonious
logistic regression models.
Table 1. Self-reported respondent characteristics by chronic pain status
(n = 80).
Characteristic
Low chronic
pain, n (%)
n = 52
High chronic
pain, n (%)
n = 28
Fisher’s
P-value
Age
13–17 31 (60) 10 (36)
0.04
18–25 21 (40) 18 (64)
Gender
Male 52 (100) 27 (96)
0.35
Female 0 (0) 1 (4)
Race
White (only) 45 (87) 16 (57)
0.01
Non-white* 7 (13) 12 (43)
Ethnicity
Hispanic 6 (14) 5 (12)
0.73
Non-Hispanic 46 (86) 38 (88)
Health insurance†
Medicaid or VA only‡ 12 (24) 12 (43)
0.03
Commercial only 27 (54) 8 (29)
Both 4 (8) 3 (11)
Insured type
unknown
7 (14) 2 (7)
Uninsured 0 (0) 3 (11)
Bleeding disorder
Haemophilia A 47 (90) 26 (93)
0.31
Haemophilia B 5 (10) 2 (7)
Severity
Moderate 5 (10) 2 (7)
0.31
Severe 47 (90) 26 (93)
Inhibitor development
Ever 22 (42) 15 (54)
0.36
Never 30 (58) 13 (46)
Treatment regimen
On demand 8 (15) 3 (11)
0.74
Prophylaxis 44 (85) 25 (89)
*Most (73%) of non-white respondents were black or African American,
14% were mixed race, 9% were Asian and 5% were American Indian or
Alaskan native.
†n = 78, two patients answered ‘Don’t Know’ to whether or not they had
health insurance and were not included.
‡Only two patients had VA only insurance, the others had Medicaid only.
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Discussion
This study provides evidence that among AYAs with
moderate or severe haemophilia, better adherence to
prescribed treatment regimens (either prophylactic or
on demand) is associated with a significantly lower
likelihood of having high levels of chronic pain.
Specifically, adjusted logistic regression analysis
revealed that for each 10-point reduction (i.e.
increase in adherence) in the experimental VERI-
47.4
53.6
51.5
49.7
48.0
53.1
30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 110.0 120.0
VERITAS-Pro (n = 44)
VERITAS-Pro (n = 25)
VERITAS-PRN (n = 8)
VERITAS-PRN (n = 3)
VERITAS-Combined (n = 52)
VERITAS-Combined (n = 28)
Chronic Pain Level
Low
High
= mean
P = .05
P = .08
Fig. 1. Box plot of prescribed treatment regimen adherence by chronic pain status (n = 80).
Table 2. Logistic regression analyses evaluating the relationship between a 10-point decrease in VERITAS (i.e. increase in adherence to prescribed clotting-
factor treatment regimen) and self-reported high (vs. low) levels of chronic pain.
Model
Prophylactic patients (n = 69) Prophylactic and On-demand patients (n = 80)
OR 95% CI P-value OR 95% CI P-value
Crude 0.68 0.45, 1.02 0.06 0.72 0.49, 1.05 0.09
Fully adjusted* 0.68 0.42, 1.09 0.11 0.69 0.44, 1.11 0.12
Final parsimonious† 0.61 0.39, 0.96 0.03 0.65 0.44, 0.96 0.03
*Fully adjusted model includes VERITAS score, age, race, ethnicity, insurance status, inhibitor development, bleeding disorder type, bleeding disorder
severity and history of inhibitor development.
†The final parsimonious model includes VERITAS score, race and history of inhibitor development.
Table 3. Final parsimonious logistic regression models evaluating the relationship between adherence to prescribed clotting-factor treatment regimen and
self-reported high (vs. low) levels of chronic pain.
Variable
Prophylactic patients (n = 69) Prophylactic and On-demand patients (n = 80)
OR 95% CI P-value OR 95% CI P-value
Increase in adherence
10-point decrease in VERITAS 0.61 0.39, 0.96 0.03 0.65 0.44, 0.96 0.03
Race
Non-white* 4.42 1.21, 16.1 0.02 5.31 1.62, 17.4 0.01
White 1.00 1.00
Inhibitor development†
Ever 1.44 0.45, 4.61 0.54 1.31 0.44, 3.89 0.62
Never 1.00 1.00
*Most (73%) of non-white respondents were black or African American, 14% were mixed race, 9% were Asian and 5% were American Indian or Alas-
kan Native.
†Inhibitor development, though not a statistically significant predictor of having high chronic pain, was included in the final model because of its
confounding influence on the primary risk factor of interest (i.e. VERITAS score) and because it increased the precision of the model (i.e. reduced the
standard error of VERITAS score parameter).
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TAS-combined (Pro and PRN) and the VERITAS-
Pro score there was a statistically significant 35%
and 39% reduction in the odds of having high
chronic pain, respectively, among moderate or severe
AYA haemophilia patients. Although previous stud-
ies have attempted to document the relationship
between adherence and health outcomes [8], this is
the first study to assess the relationship using a vali-
dated scale of adherence. Moreover, this study’s pri-
mary health outcome of interest (chronic pain) is
well-known to be one of the most serious problems
afflicting those with haemophilia [14]. Chronic pain
has long been known to diminish physical, emo-
tional and social aspects of quality of life and
contribute to increased health care utilization and
long-term disability [15–19].
Many factors are thought to influence haemophilia
treatment adherence, including knowledge about the
disease and the importance of treatment, disease sever-
ity and the frequency of haemophilia symptoms, treat-
ment satisfaction, frequency of administration, the
amount of time spent in an HTC, reminder telephone
calls, the age of the PWH and the quality of relation-
ships among patients and their health care profession-
als [2,8,20–23]. Yet, improving adherence still
remains a difficult task. Broadly, a previous systematic
review revealed that the most successful strategies
across several types of chronic disease have included:
education with behavioural support, reminder/recall
systems and pharmacist-led, multicomponent interven-
tions [24]. On the basis of results from this study that
show a relationship between adherence to clotting-fac-
tor treatment and level of chronic pain – these strate-
gies, along with other novel approaches, should be
continuously evaluated in the haemophilia population,
especially in AYAs.
Compared to the general haemophilia population,
AYA PWH are unique in that as children transition
into young adulthood, their activity level may change,
which could affect the risk of bleeding. Likewise,
social pressures and/or lifestyle changes may interfere
with their adherence to prophylaxis (i.e. prophylaxis
may become a lower priority for the patient during
adolescence). Moreover, AYAs often begin taking
responsibility for self-treatment of haemophilia [2,25].
Previous research has suggested that as many as two-
thirds of young adults will experiment with stopping
or reducing prophylactic dosing [26] and that AYA
PWH are not only less adherent to prophylaxis but
that AYA PWH perceive the need for prophylaxis as
unimportant [2]. Although no randomized controlled
trials have been done to demonstrate the efficacy of
prophylaxis in adolescents, there is evidence that
continuing prophylaxis, or starting secondary prophy-
laxis, reduces the risk of bleeding and helps preserve
joint health and quality of life [27,28]. This study
reinforces the need to provide resource support neces-
sary for AYA PWHs to achieve optimal adherence to
prescribed clotting-factor treatment regimens – as this
may reduce the likelihood of having high levels of
chronic pain.
Another interesting (and surprising) finding from
this study was that non-white AYA patients with
moderate or severe haemophilia were >4 times as
likely as whites to report high levels of chronic pain.
This was true among both prophylactic-only and all
patients. This finding is particularly concerning
because it remained even after statistical adjustment
for demographic (e.g. insurance status and age) and
clinical factors (e.g. severity and inhibitor develop-
ment). Previous research, though not specific to PWH,
has shown that African American children have signif-
icantly higher postoperative pain scores and require
more morphine than white children [29]. A systematic
review of racial disparities in pain management sup-
ports our findings and suggested that significant racial
and ethnic disparities exist in both evaluating pain
and providing adequate analgesics. Specifically, racial
minorities were more likely to experience greater pain
and worse pain management across a variety of health
care settings including acute pain managed in the
emergency department, postoperative care, childbirth,
chronic non-cancer pain, arthritis pain, cancer-related
pain and end-of-life care [30]. Moreover, previous
research has suggested that compared to whites,
blacks with chronic pain experience greater pain
severity, more disability and heightened psychosocial
problems related to their pain, including depression,
post-traumatic stress disorder and anxiety [31,32].
Another report suggested that patients receiving
plasma-derived activated prothrombin complex con-
centrates (pd-aPCC) were more likely to be African
American [33], which may suggest that our inhibitor
(ever vs. never) designation may not fully control for
the impact of inhibitor development. Future research
should more thoroughly examine the relationship
between race and chronic pain among PWH.
This study has limitations. Primarily, data are cross-
sectional, thus causal inference cannot be made. Specif-
ically, although study results support that adherence to
clotting-factor treatment regimen and level of chronic
pain are strongly related among moderate and severe
haemophilia AYA patients, the directionality of this
relationship cannot be confirmed. That is, though we
modelled how self-reported level of adherence impacts
the odds of having high chronic pain – it is also possi-
ble that level of chronic pain impacts adherence. This
cannot be teased out in a cross-sectional study and
should be examined in the future with prospective
studies. A second limitation is that all data are self-
reported. As such, information about blood disorder
type and severity, health insurance coverage and other
demographic, clinical and behavioural information are
not confirmed by medical record review or administra-
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tive claims data. However, by obtaining data through
self-report, this study was able to collect important,
reliable and valid patient-report outcomes (PRO) data
about adherence and chronic pain. Patient-reported
data about pain are considered the ‘gold standard’ and
the VERITAS scales are the only validated measures of
adherence to clotting-factor treatment developed to
date. Another limitation is that the VERITAS-com-
bined score that we reported, though it statistically
comprised of two validated instruments, is an experi-
mental, non-validated measure that has not been previ-
ously reported. Most participants (86%), however,
treated prophylactically, and VERITAS-Pro scores,
which have been previously validated, confirmed the
results of the experimental, combined score. Finally,
AYA PWH were primarily recruited from large
national or regional haemophilia meetings. Thus, our
convenience sample of AYA PWH may not adequately
represent the broader AYA PWH population who do
not typically attend these meetings.
Conclusion
This study provides evidence that among AYAs with
moderate or severe haemophilia, better adherence to
prescribed clotting-factor treatment regimens (either
prophylactic or on demand) is associated with a signifi-
cantly lower likelihood of having high levels of chronic
pain. As AYA PWH transition into early adulthood
and often begin taking responsibility for self-treatment
of haemophilia [2] maintaining adherence becomes
increasingly important. Future studies should seek to
confirm the association between clotting-factor adher-
ence and chronic pain among AYA PWH, evaluate
strategies to improve adherence in this group, and to
explore why non-whites were more than four times as
likely as whites to report high levels of chronic pain.
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